Pharmaceutical companies turn to AI to speed up drug discovery
Pharmaceutical companies turn to AI to speed up drug discovery
The pharmaceutical industry is currently undergoing a massive transformation as companies turn to Artificial Intelligence to tackle the "innovation crisis."
AI is now acting as a "force multiplier," allowing researchers to analyze vast datasets to identify biological targets and design new molecules in days rather than months.
By using predictive modeling to filter out ineffective candidates early, companies can save substantial time and money.
While challenges like data quality, the "black box" nature of models, and a lack of specialized talent persist, the trend is undeniable.
Newer "AI-first" biotech firms are forcing traditional giants to adapt or form strategic partnerships.
